Bristol-Myers Squibb/ImaRx Pharmaceutical
This article was originally published in The Gray Sheet
Executive Summary
Firms enter into licensing agreement whereby Bristol-Myers acquires manufacturing and marketing rights to SonoRx, an orally administered ultrasound contrast agent developed by ImaRx. According to Bristol-Myers, "SonoRx may allow physicians to see . . . internal organs more easily by eliminating the gas artifacts that can prevent clear delineation of structures" during abdominal ultrasound procedures. The firm says it intends to submit an investigational new drug application for SonoRx in 1993 and complete clinical trials during 1994. It adds that its subsidiary Westwood Squibb of Buffalo, New York will manufacture the agent.